eCommons@AKU
Woman and Child Health

Division of Woman and Child Health

December 2010

Zinc supplementation for the prevention of
pneumonia in children aged 2 months to 59
months
Zohra S. Lassi
Aga Khan University

Batool A. Haider
Aga Khan University, batool.ali@aku.edu

Zulfiqar Ahmed Bhutta
Aga Khan University, zulfiqar.bhutta@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_wc
Part of the Pediatrics Commons
Recommended Citation
Lassi, Z., Haider, B., Bhutta, Z. A. (2010). Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59
months. Cochrane Database of Systematic Reviews(12), 5978.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_wc/89

Cochrane Database of Systematic Reviews

Zinc supplementation for the prevention of pneumonia in
children aged 2 months to 59 months (Review)
Lassi ZS, Moin A, Bhutta ZA

Lassi ZS, Moin A, Bhutta ZA.
Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months.
Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD005978.
DOI: 10.1002/14651858.CD005978.pub3.

www.cochranelibrary.com

Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

TABLE OF CONTENTS
HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . .
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . .
BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . .
ACKNOWLEDGEMENTS
. . . . . . . . . . . . . . . . . . . . . . . . .
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . .
DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Zinc supplementation vs placebo, Outcome 1 Pneumonia incidence.
Analysis 1.2. Comparison 1 Zinc supplementation vs placebo, Outcome 2 Pneumonia prevalence.
ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . .
APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FEEDBACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . .
DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . .
SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . .
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . .
INDEX TERMS
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

1
1
2
3
4
5
5
6
8
9
10
11
12
13
13
17
31
31
32
32
33
36
37
37
38
38
38
39
39

i
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ABSTRACT
Background
Pneumonia is a leading cause of morbidity and mortality in children younger than five years of age. Most deaths occur during infancy
and in low-income countries. Daily zinc supplements have been reported to prevent acute lower respiratory tract infection (LRTI) and
reduce child mortality. This is an update of a review first published in 2010.
Objectives
To evaluate the effectiveness of zinc supplementation in the prevention of pneumonia in children aged two to 59 months.
Search methods
We searched CENTRAL (Issue 21 October 2016), MEDLINE (1966 to October 2016), Embase (1974 to October 2016), LILACS
(1982 to October 2016), CINAHL (1981 to October 2016), Web of Science (1985 to October 2016) and IMSEAR (1980 to October
2016).
Selection criteria
Randomised controlled trials (RCTs) evaluating zinc supplementation for the prevention of pneumonia in children aged from 2 months
to 59 months.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data.
Main results
We did not identify any new studies for inclusion in this update. We included six studies that involved 5193 participants.
Analysis showed that zinc supplementation reduced the incidence of pneumonia by 13% (fixed-effect risk ratio (RR) 0.87; 95%
confidence interval (CI) 0.81 to 0.94, six studies, low-quality evidence) and prevalence of pneumonia by 41% (random-effects RR
0.59; 95% CI 0.35 to 0.99, one study, n = 609, low-quality evidence). On subgroup analysis, we found that zinc reduced the incidence
of pneumonia defined by specific clinical criteria by 21% (i.e. confirmation by chest examination or chest radiograph) (fixed-effect RR
0.79; 95% CI 0.71 to 0.88, four studies, n = 3261), but had no effect on lower specificity pneumonia case definition (i.e. age-specific
fast breathing with or without lower chest indrawing) (fixed-effect RR 0.95; 95% CI 0.86 to 1.06, four studies, n = 1932).
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Authors’ conclusions
Zinc supplementation in children is associated with a reduction in the incidence and prevalence of pneumonia.

PLAIN LANGUAGE SUMMARY
Zinc supplementation for the prevention of pneumonia in children aged two to 59 months
Review question
We evaluated the effectiveness of zinc supplementation to prevent pneumonia in children aged from two to 59 months.
Background
Zinc is an essential element for children’s growth and development. Too little zinc is associated with increased risk of infection,
particularly diarrhoea and pneumonia. Children are more prone to zinc deficiency because they are less able to absorb dietary zinc
and some children, especially in low-income countries, may not have received enough zinc from their mothers before birth. Zinc
supplements for children has been reported to prevent pneumonia.
Search date
We searched the literature up to October 2016. This is an update of a review published in 2010. We did not find any new studies for
this update.
Study characteristics
We included six studies that investigated zinc supplements to prevent pneumonia. The studies were conducted in Bangladesh, India,
Peru and South Africa and involved 5193 children aged from two to 59 months. Children received either zinc or a similar-looking
treatment that did not contain zinc. In two studies, children were also given vitamin A.
Study funding sources
All included studies were funded. Of these, three explicitly mentioned that funding agencies had no role in the design and results of
the study.
Key results
Zinc supplementation was significantly associated with reducing the incidence and prevalence of pneumonia among children aged from
two to 59 months. On subgroup analysis, we found that a more stringent diagnosis (radiological examination) increased the reduction
in pneumonia incidence.
Quality of the evidence
Overall, evidence quality was assessed as low on GRADE assessment.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]

Zinc supplementation compared with placebo for the prevention of pneumonia in children aged 2 months to 59 months
Patient or population: children aged 2 m onths to 59 m onths
Settings: Bangladesh, India, Peru, South Af rica
Intervention: zinc supplem entation
Comparison: placebo
Outcomes

Pneumonia incidence

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence Comments
(GRADE)

Assumed risk

Corresponding risk

Placebo

Zinc supplementation

343 per 1000

299 per 1000
(278 to 323)

RR 0.87
(0.81 to 0.94)

5193
(6 studies)

⊕⊕
low1,2

13 per 1000
(8 to 22)

RR 0.59
(0.35 to 0.99)

609
(1 study)

⊕⊕
low3,4

Pneumonia prevalence 22 per 1000

* The basis f or the assumed risk (e.g. the m edian control group risk across studies) is provided in f ootnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI).
CI: Conf idence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the estim ate of ef f ect.
M oderate quality: Further research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate.
Low quality: Further research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate.
Very low quality: We are very uncertain about the estim ate.
1

Studies have unclear inf orm ation on allocation concealm ent, blinding and reporting biases.
Pneum onia diagnosis criteria was used dif f erently.
3
Studies have lim ited inf orm ation on blinding of outcom es assessors and reporting bias.
4 Total num ber of events were less than 300.
2

3

BACKGROUND

Description of the condition
Pneumonia is the largest cause of childhood mortality, accounting
for 15% of all childhood deaths under five years (WHO 2015),
and 19% of all childhood deaths in low-income countries (Bryce
2005; Rudan 2008). Pneumonia is diagnosed by the presence of
either fast breathing or lower chest wall indrawing (WHO 2015)
in children aged under five years. Presenting features in viral or
bacterial pneumonia are similar, however wheezing is more common in children with viral pneumonia.
Pneumonia can be prevented by immunising against Haemophilus
influenzae type B (Hib), pneumococcus, measles and pertussis
(whooping cough) (WHO 2015). Nutrition including breastfeeding for the first six months of life plays a major role by boosting immunity against causative organisms of pneumonia (WHO
2015). Good hygiene and clean indoor air also help in preventing
pneumonia (WHO 2015).
Rudan 2013 identified five risk factors for pneumonia: malnutrition, low birth weight, nonexclusive breast feeding, solid fuel use
and overcrowding. By 2010, pneumonia episodes for children aged
under four years in low- and middle-income countries (LMICs)
decreased by 25% over the past decade to about 0.22 episodes per
child per year when exposure to the five risk factors decreased by
20% to 30% (Rudan 2013). Therefore, any interventions that can
improve child survival from pneumonia are important.
According to the World Health Organization (WHO), zinc deficiency accounts for 13% of all lower respiratory tract infection
(LRTIs) (WHO 2009). Acute LRTI is a leading cause of mortality
among children aged under five years (Bryce 2005; Rudan 2008),
and which is responsible for nearly two million deaths annually,
mainly in low-income countries.

decreased immunocompetence as well as subclinical inflammation; moderate-to-severe deficiency can lead to diarrhoea; and severe deficiency produces dermatitis and alopecia (Krebs 2014).
There is evidence that preventative zinc supplementation reduces
pneumonia morbidity (Bhutta 1999; Yakoob 2011) and is beneficial in reducing diarrhoeal episodes in children with acute and
persistent diarrhoea (Bhandari 1994; Zinc Group 2000). However, there is insufficient evidence to support preventive zinc supplementation or adjunctive zinc supplementation with antibiotics
to reduce pneumonia-specific mortality (Haider 2011; Yakoob
2011). Zinc supplements (zinc sulphate, zinc gluconate, zinc acetate) can be administered as tablets, syrup or powder. However,
zinc supplements need to be administered with caution because
excess levels may cause toxicity.

How the intervention might work
Zinc plays an important role in cell regeneration, immunity and
growth (Krebs 2014; Shankar 1998). Zinc deficiency decreases
T-lymphocytes and T-helper, impairs macrophage function and
reduced killer cells (Ibs 2003; Ravaglia 2000), and adversely impacts innate immunity affecting interferon (IFN) gamma production, interleukin-2 (IL-2) and tumour necrosis factor-α (TNF-α)
(Krebs 2014). Zinc supplementation in children increases levels
of complement in the blood that modulate the function of Tlymphocytes, T-helper, macrophages and neutrophils and hence
improves the ability to fight infection. Zinc supplementation improves circulating levels of T-lymphocytes and other macrophages
that enhance ability to fight infection (Fraker 1993). Zinc is not
stored in the body, but repletion is straightforward. Children with
diarrhoea can become zinc deficient quickly. Furthermore, if zinc
deficiency occurs during periods of growth, it can be conducive to
growth faltering as is shown by a review that found correlation between dietary zinc inadequacy and stunting among children aged
under four years (Krebs 2014; Wessells 2012).

Description of the intervention
In 2005, zinc intake was inadequate among 17.3% of the world’s
population; rates of zinc adequacy are lower in sub-Saharan Africa
and South Asia (Wessells 2012). The World Bank described multiple factors such as low animal food intake, less bioavailability of
dietary zinc, and zinc loss during events of diarrhoea (Bhutta 1999;
Black 1998) that could potentially lead to zinc deficiency in lowincome settings (World Bank 2016). The WHO estimated that
zinc deficiency may be related to 800,000 deaths a year, with more
than 50% occurring in children under five years of age. Children
are more susceptible to zinc deficiency because of lower rates of
intestinal absorption and from starting life with low body stores
due to intrapartum under-nutrition (Krebs 2014).
Mild-to-moderate zinc deficiency is associated with impaired
physical growth, delayed sexual maturity, behavioural disturbances, anorexia, affected permeability of the intestinal tract and

Why it is important to do this review
Bhutta 1999 showed that zinc was associated with a reduced incidence of pneumonia. Aggarwal 2007 included more recent studies, but included children aged between birth and 59 months who
were given zinc supplements for at least a few months. Roth 2010
calculated the effect size by case definition of pneumonia, and
included studies that administered zinc supplements to children
aged between birth and 59 months. Yakoob 2011 focused on zinc
supplementation for more than three months in children aged under five years and found evidence to support the positive impact
of zinc supplementation on diarrhoeal and pneumonia morbidity and mortality to include it in the LiST tool. However Yakoob
2011 did not include low birth weight or small-for-gestational
age infants, nor provide a specific case definition for pneumonia.
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Similarly, a review by Bhutta 2013 of diarrhoea and pneumonia
interventions reported a non-significant impact of preventive zinc
supplementation on acute lower respiratory infection (ALRI)-related mortality.
We investigated zinc supplementation for at least three months in
children aged from two months to 59 months and conducted a
meta-analysis of data published up to 2011. However, with new
and upcoming trials, this review required updating.

or placebo. We excluded trials in which children were given additional supplements unless the co-interventions other than zinc
were the same in both groups. The recommended daily allowance
for infants is 5 mg of elemental zinc per day and 10 mg per day for
children aged from one to five years (RDA 1989). We included
trials in which supplements were administered for at least three
months and outcome surveillance was carried out for at least four
weeks.
Types of outcome measures

OBJECTIVES
Primary outcomes

To evaluate the effectiveness of zinc supplementation in the prevention of pneumonia in children aged two to 59 months.

METHODS

Criteria for considering studies for this review

Types of studies
We included randomised controlled trials (RCTs) evaluating supplementation of zinc for the prevention of pneumonia in children
aged from two to 59 months. We included studies that defined an
episode of pneumonia in the following ways.
1. Reported cough or difficulty in breathing with a respiratory
rate above the WHO-defined age-specific values (respiratory rate
of 50 breaths per minute or more for children aged two to 11
months, or respiratory rate of 40 breaths per minute or more for
children aged 12 to 59 months), and either documented fever
over 38°C or chest in-drawing (WHO 1990).
2. A diagnosis of pneumonia based on chest examination by a
physician.
3. A diagnosis of pneumonia based on a chest radiograph.
We included trials published in languages other than English.
Quasi-RCTs were not eligible for inclusion.
Types of participants
We included children aged from two months to 59 months.
Types of interventions
Oral supplement containing at least the USA’s recommended daily
allowance of zinc versus either an oral supplement without zinc

1. Numbers of new episodes of pneumonia in children aged
from two months to 59 months.
Secondary outcomes

1. Prevalence (number of cases of pneumonia at a given time
per total days of observation) of pneumonia in children aged
from two months to 59 months.

Search methods for identification of studies
Electronic searches
We
searched
the Cochrane Central Register of Controlled Trials (CENTRAL),
the Cochrane Library (www.thecochranelibrary.com, accessed 21
October 2016), which contains the Acute Respiratory Infections
Group’s Specialised Register, MEDLINE (November 2009 to 21
October 2016) and Embase (January 2010 to 21 October 2016).
We searched LILACS (1982 to 21 October 2016) using a new
search strategy. We also searched CINAHL (1981 to 21 October
2016) and Web of Science (1985 to 21 October 2016). Details of
previous searches are presented in Appendix 1.
We used the search strategy described in Appendix 2 to search
MEDLINE and CENTRAL. We combined the MEDLINE search
with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precisionmaximising version (2008 revision); Ovid format (Lefebvre 2011)
. We adapted the search strategy to search Embase (Appendix
3), LILACS (Virtual Health Library) (Appendix 4), CINAHL
(Appendix 5) and Web of Science (Appendix 6). We searched IMSEAR using the search terms “pneumonia” and “zinc”. We imposed no language or publication restrictions.
Figure 1 illustrates the search and study selection processes.
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Figure 1. Study flow diagram
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Searching other resources
We searched the WHO ICTRP (www.who.int/ictrp) and ClinicalTrials.gov trials registries (latest search 8 July 2016). We also
searched related conference proceedings for relevant abstracts. We
also checked the reference lists of all trials identified.

Data collection and analysis

noted this and repeated the analysis using the random-effects
method.

Dealing with missing data
We noted levels of attrition among included studies. As far as
possible, we performed analyses on an intention-to-treat (ITT)
basis. We attempted to include all participants randomised to each
group in the analyses.

Selection of studies
Two review authors independently assessed all potential studies
identified for inclusion. We resolved any disagreement through
discussion, and if required, consulted the third review author.
Data extraction and management
We designed a data extraction form. Two review authors extracted
data. We resolved discrepancies through discussion, and if required, we consulted the third review author. We entered data into
Review Manager software (RevMan 2014) and checked for accuracy. There were no new studies identified for inclusion in this
update.

Assessment of heterogeneity
We measured heterogeneity among the trials by calculating the I²
statistic, and Chi² P value. If the I² statistic exceeded 50%, and
the Chi² P value was less than 0.1, we would have considered heterogeneity to be substantial. We did not find any heterogeneity;
therefore, we did not attempt subgroup analyses based on differences in zinc dosage, participants’ age, supplementation in healthy
children compared with children recovering from an episode of
illness, and pre-intervention zinc levels. However, we attempted
to look for the differential effect of zinc supplementation on the
case definition of ALRI.

Assessment of risk of bias in included studies

Assessment of reporting biases

There were no new studies identified for inclusion for this update.
For the 2010 version of this review (Lassi 2010), two review authors (ZSL, BAH) independently assessed risk of bias using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We resolved any disagreement by
discussion with the third review author (ZAB).

We aimed to assess reporting bias by comparing published study
reports with study protocols. We planned to assess for the presence
of publication bias by looking for funnel plot asymmetry; however,
the low number of included studies meant this was not feasible.

Data synthesis
Measures of treatment effect
For dichotomous outcomes, we extracted the total number of participants for each group and numbers of participants experiencing
an event. We used risk ratio (RR) and 95% confidence intervals
(CIs) to describe effect sizes.
Unit of analysis issues
We carried out statistical analysis using RevMan 2014). Initially,
we used fixed-effect inverse variance meta-analysis to combine data
where trials examined the same intervention, and study populations and methods were judged sufficiently similar. Where we suspected clinical or methodological heterogeneity between studies
sufficient to suggest that treatment effects may differ between trials, we conducted random-effects meta-analysis. When we identified substantial heterogeneity in a fixed-effect meta-analysis, we

We carried out statistical analysis using RevMan 2014 software. In
the absence of significant heterogeneity, we used the fixed-effect
meta-analysis model for combining data.

Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis based on diagnosis of
pneumonia.

Sensitivity analysis
We planned to carry out a sensitivity analysis to explore the effect of
trial quality (assessed by concealment of allocation), by excluding
studies with clearly inadequate allocation concealment. However,
only two studies had adequate allocation concealment, therefore
we did not run the sensitivity analysis.
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RESULTS

Description of studies
See Characteristics of included studies, Table 1 and Characteristics
of excluded studies tables.

Results of the search
This is an update of a review previously published in 2010 (Lassi
2010). The most recent search (to October 2016) did not identify
any new studies for inclusion.

Included studies
We included six trials. These studies were from Bangladesh (Brooks
2005), India (Bhandari 2002; Sazawal 1998), Peru (Penny 2004),
and South Africa (Bobat 2005; Luabeya 2007).
Penny 2004 conducted a randomised, double-blind, placebo-controlled community-based trial in Lima, Peru that involved 238
children with diarrhoea for more than 14 days who were aged from
six to 36 months. Children were randomised to receive zinc alone,
zinc plus vitamins or placebo for two weeks. Childrens’ characteristics at baseline were similar except for sex and length-for-age Z
scores.
Brooks 2005 conducted a study in a low-income population in
an urban setting of Dhaka, Bangladesh. The study included 1665
children aged from 60 days to 12 months who were randomly
allocated to receive oral zinc (70 mg) or placebo once weekly.
Children were assessed weekly in the children’s homes. Children
with suggestive respiratory disease or diarrhoea were referred to
clinics where they were assessed and diagnoses made based on the
WHO criteria.
Bhandari 2002 included 2482 children aged six to 30 months who
were from urban slums in New Delhi, India. Children received
daily elemental zinc (10 mg for infants; 20 mg for older children) or
placebo for four months. Both groups received single dose vitamin
A (100,000 IU for infants and 200,000 IU for older children) at
enrolment. Both groups were comparable on socio-demographic
profile, anthropometry, child feeding practices, morbidity in the
previous 24 hours, and plasma zinc concentration.
Luabeya 2007 included children aged from four to six months
from the KwaZulu-Natal Province of South Africa. Children were
randomised to two intervention arms and one control arm. Children in the control arm received vitamin A only; in the first intervention arm they were given vitamin A plus zinc; and in the
second intervention arm children received vitamin A, zinc and
multiple micronutrients. Children received supplements until 24
months of age, thus each child received zinc supplements for 18 to
20 months. Among the participants, 32 children were born with

HIV positive status, and 154 were born without HIV infection
to HIV positive mothers. Groups differed on weight-for-length
scores.
The double-blind controlled trial by Sazawal 1998 was conducted
in a low socioeconomic population of 609 children aged between
six and 35 months in urban India. Children were assigned to
zinc supplementation (n = 298) and placebo (n = 311) groups.
Children in the treatment group received 10 mg elemental zinc
and placebo group children received a substance similar in colour
and taste. The daily fixed dose of 5 mL per child was given to all
enrolled children for six months, but this was increased to 10 mL
for children with diarrhoeal illnesses. The baseline characteristics
of included children were similar for age, sex, nutritional status
and baseline plasma zinc.
Bobat 2005 conducted a randomised, double-blind, placebo-controlled equivalence trial of zinc supplementation at Grey’s Hospital in Pietermaritzburg, South Africa. The study included 96 children aged from six to 60 months with HIV 1 infection who were
randomly assigned to receive 10 mg of elemental zinc sulphate or
placebo daily for six months. Baseline characteristics of included
children were similar.
Excluded studies
We excluded 30 studies that did not satisfy inclusion criteria. Seven
studies included children outside the age limits of our review criteria (Lira 1998; McDonald 2015; Osendarp 2002; Sur 2003;
Taneja 2009; Tielsch 2007 (also reported a different response to
intervention definition than we used); Vakili 2009). We excluded
seven studies that provided supplements for less than three months
(Baqui 2002; Castillo-Duran 1987; Chandyo 2010; Feiken 2014;
Rahman 2001; Roy 1999; Sempértegui 1996). We excluded 14
studies that applied different case definitions for ALRI/pneumonia, which were not based on WHO criteria, radiograph or chest
examination by physician (Baqui 2003; Larson 2010; Long 2006;
Lind 2004; Malik 2014; Mazoomar 2010; Ninh 1996; Reul 1997;
Richard 2006; Sampaio 2013; Sanchez 2014; Soofi 2013; Rosado
1997; Umeta 2000). We excluded one study because children received zinc supplement in a fortified drink (Bates 1993). We also
excluded one study (Adhikari 2016) because it had included children with recurrent infections.
Please refer to Characteristics of excluded studies for further details.

Risk of bias in included studies
Figure 2 and Figure 3 provide graphical summaries of the ’Risk of
bias’ assessment for the six included studies. With one exception
(Penny 2004), studies were assessed as providing low or unclear
risk of bias in relation to methods. Luabeya 2007 had the lowest
risk of bias; Penny 2004 was assessed at unclear risk of bias.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study
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Allocation
Most included studies were assessed as demonstrating adequate sequence generation and used computer-generated sequencing techniques (Bhandari 2002; Bobat 2005; Brooks 2005; Luabeya 2007;
Sazawal 1998). Allocation concealment was adequate three studies
(Bhandari 2002; Luabeya 2007; Sazawal 1998); the remainder did
not report in sufficient detail to enable assessment (Bobat 2005;
Brooks 2005; Penny 2004).

Blinding
Blinding of participants and study personnel was achieved in four
studies (Bobat 2005; Brooks 2005; Luabeya 2007; Sazawal 1998).
The remaining studies reported insufficient information to permit
judgement (Bhandari 2002; Penny 2004).
Blinding of outcome assessors was achieved in Brooks 2005 and
Luabeya 2007. Brooks 2005 reported that blinding was not affected because a proportion of children in both the zinc and
placebo groups reacted to the taste such that treatment could not
be distinguished; Luabeya 2007 reported that outcomes assessors
were blinded to assignment.

Incomplete outcome data
Attrition and exclusions were described in all except studies Penny
2004 and Sazawal 1998. The other four studies (Bhandari 2002;
Bobat 2005; Brooks 2005; Luabeya 2007) reported reasons for
exclusions; these included refusal to participate, moved outside
the study site, taste of the syrup, and death.

Selective reporting
Only Luabeya 2007 was registered with a trials register. None of
the other studies had published protocols (Bhandari 2002; Bobat
2005; Brooks 2005; Penny 2004; Sazawal 1998). However, all
proposed outcomes were reported.

All six studies reported the incidence of pneumonia (Bhandari
2002; Bobat 2005; Brooks 2005; Luabeya 2007; Penny 2004;
Sazawal 1998), while one study (Sazawal 1998) also reported
prevalence rates.
Incidence of pneumonia

Administration of zinc supplementation showed a statistically significant impact on reducing pneumonia incidence by 13% (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.81 to 0.94, fixed-effect model, six studies, n = 5193, low-quality evidence). There was
no heterogeneity (I² statistic = 28%, Chi² test P = 0.20; Analysis
1.1).
We pooled studies that used similar case definitions. Studies that
used clinical definitions of age-specific fast-breathing, with or
without lower chest indrawing did not exhibit impact from zinc
supplementation on reducing pneumonia (RR 0.95, 95% CI 0.86
to 1.06, fixed-effect model, four studies, n = 1932). There was no
heterogeneity (I² statistic = 0%, Chi² test P = 0.74).
Studies that applied case definition for pneumonia based on chest
examination or chest radiograph exhibited significant impact from
zinc supplementation on reducing incidence of pneumonia by
21% (RR 0.79, 95% CI 0.71 to 0.88, fixed-effect model, four
studies, n = 3261). There was no heterogeneity (I² statistic = 0%,
Chi² test P = 0.44). Bobat 2005 included children with HIV. When
this study was removed from the analysis there was no difference
in results (RR 0.88, 95% CI 0.81 to 0.95, fixed-effect model, three
studies, n = 3165). Evidence was low quality (Summary of findings
for the main comparison).
Prevalence of pneumonia

Administration of zinc supplementation showed a statistically significant impact on reducing the pneumonia prevalence by 41%
among children aged from two to 59 months (RR 0.59, 95% CI
0.35 to 0.99, fixed-effect model, one study, n = 609, low-quality evidence; Analysis 1.2). (Summary of findings for the main
comparison).

Other potential sources of bias
The funding agencies were reported to have had no input to design or study results in three studies (Bobat 2005; Brooks 2005;
Luabeya 2007). Bhandari 2002; Penny 2004 and Sazawal 1998
did not mention the role of funding agencies explicitly.

DISCUSSION

Summary of main results
Effects of interventions
See: Summary of findings for the main comparison Zinc
supplementation compared with placebo for the prevention of
pneumonia in children aged 2 months to 59 months

This is an update of a review first published in 2010 and included
no new studies. Previous conclusions are unchanged.
We included six randomised controlled trials (RCTs) evaluating
the impact of zinc supplementation in children aged from two to
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59 months. Our meta-analysis indicated that zinc supplementation led to reductions in the incidence of pneumonia by 13% and
pneumonia prevalence by 41%. The greater overall reduction of
pneumonia prevalence result is due to prevalence data originating
from one study.
We found that zinc reduced pneumonia incidence (defined by
specific clinical criteria and confirmed by chest examination or
chest radiograph) by 21%. We found an expected association of
acute lower respiratory infection (ALRI) case definition with an
effect size (P = 0.02). We found benefits of zinc supplementation
when ALRI was diagnosed following clinical examination or chest
radiography suggesting infection.
Reduction in pneumonia incidence supports the use of zinc supplements among children two to 59 months of age. Because zinc is
not stored in the body, adequate zinc needs to be available in daily
diet (Sanstead 1995). Children, particularly those from low-income countries who have inadequate intake of food that contains
zinc (mainly foods of animal origin) should receive supplements
to address deficiency.

Overall completeness and applicability of
evidence
Our findings from can be extrapolated for children living in
low- and middle-income countries because most included studies were from disadvantaged urban areas of low-income countries
(Bangladesh, India, Peru, and South Africa). In two studies, either
children or their mothers had HIV positive status (Bobat 2005;
Luabeya 2007). In most studies, children were excluded if they had
co-morbidities such as tuberculosis, congenital heart disease, less
than 60% median weight-for-age Z score, and nutritional oedema.
Penny 2004 recruited children on their breastfeeding status. The
use of consistent and accurate definitions of pneumonia, with emphasis on clinical documentation of key signs or radiographic diagnosis, would avoid misclassification and lead to greater confidence in study findings.

Quality of the evidence
We assessed that review outcomes were low according to GRADE
criteria. We downgraded evidence quality because outcomes were
ascertained using different criteria and ’Risk of bias’ assessment. Of
note, half of the included studies reported pneumonia according
to the WHO definition (WHO 1990); the remainder relied on
clinical examination and chest radiographs. We therefore looked
for differential effects on outcome estimates with respect to case
definition and reported their impact separately.
Allocation concealment was adequately described overall. All included studies were deemed to be adequately blinded for treatment assignment. Completion rates were greater than 90% in four
included studies; Penny 2004 reported completion by 16% of par-

ticipants and Sazawal 1998 did not report numbers of participants
who dropped out. The low levels of missing data meant that we
chose not to assess the impact on overall estimates because it was
not anticipated to cause significant bias in the study results.

Potential biases in the review process
We undertook a systematic search of the literature to identify all
studies that met our inclusion criteria. Study selection and data
extraction decisions were cross-checked independently by the review authors. Included studies were not free from bias; only one
study was assessed at low risk of bias for all domains. We could not
assess reporting bias because of the limited numbers of included
studies.

Agreements and disagreements with other
studies or reviews
We found RCT evidence from both high- and low-income countries showing an effect of zinc in decreasing morbidity and mortality in children due to respiratory and gastro-intestinal infections
(Hambidge 1999; Sazawal 1998). The effect of zinc against infectious diseases is therapeutic as well as preventive.
Findings reported by the Zinc Investigators’ Collaborative Group
in (Bhutta 1999) and Aggarwal 2007 were consistent with our
review. Bhutta 1999 reported that children who received zinc supplements had positive effects for pneumonia (odds ratio (OR)
0.59, 95% CI 0.41 to 0.83). Moreover, Bhutta 1999 included
trials that administered zinc supplements with therapeutic intent,
which might have led to an overestimation of the potential preventive effects of zinc. Aggarwal 2007 included trials that recruited
children aged from birth to 59 months who were provided zinc
supplementation for at least three months; analysis showed 20%
decreased incidence of respiratory illness among children supplemented with zinc compared with placebo. Similar findings were
reported by Roth 2010 who also assessed specific case definitions
for impact evaluation of children aged from birth to five years.
Roth 2010 reported that zinc reduced ALRI incidence defined by
specific clinical criteria (incidence rate ratio (IRR) 0.65, 95% CI
0.52 to 0.82), compared with no effect on lower-specificity ALRI
case definitions based on caregiver reports (IRR 1.01, 95% CI
0.91 to 1.12) or WHO non-severe pneumonia (IRR 0.96, 95%
CI 0.86 to 1.08).

AUTHORS’ CONCLUSIONS
Implications for practice
We found sufficient evidence to support the use of zinc supplementation for children aged from two to 59 months to prevent
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pneumonia. Our analysis supports use of preventive zinc supplementation to improve child health.

sidered in which the effectiveness of zinc supplementation should
be assessed for acute pneumonia provided that cases are well-defined by strict clinical criteria.

Implications for research
More well-designed, large-scale randomised controlled trials
(RCTs) are needed to establish the benefit of zinc supplementation for preventing pneumonia among children aged from two to
59 months. Development of effective and feasible interventions
to improve zinc status in children is essential. Enhancement of
bioavailable zinc in foods by genetic engineering, plant breeding
and periodical supplementation are other possible intervention
strategies that should be evaluated.
Given the rising burden of child mortality due to respiratory infections, particularly pneumonia, and considering its decreasing
impact with zinc supplementation, further reviews should be con-
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]
Bhandari 2002
Methods

RCT in which the children were individually randomised by a computer-generated
simple randomisation scheme in blocks of 8. Zinc or placebo bottles were labelled with a
unique child identification number according to the randomisation scheme. Six bottles,
one for each month and two extra, for each child were produced and labelled before
enrolment commenced. The supplies for each child were kept separately in labelled plastic
bags. The zinc and placebo syrups were similar in appearance, taste, and packaging.
Blinding was maintained during analyses by coding the groups as A or B
The study took place in the urban slum of Dakshinpuri in New Delhi, India. For episodes
to be counted as individual, there had to be at least 14 intervening days. The children in
the two groups were comparable for age, anthropometry, child feeding practices, morbidity in the previous 24 hours, socioeconomic characteristics and plasma zinc concentration

Participants

The study included children aged from 6 to 30 months. There were 1241 children in
each group, and after dropouts, the number reduced to 1093 in the zinc and 1133 in the
placebo groups. Children were excluded if consent was refused, were likely to move out
of the study area within the next four months, needed urgent admission to hospital on
the enrolment day or had received a massive dose of vitamin A (100,000 IU for infants
and 200,000 IU for older children) within the two months before enrolment

Interventions

Doses of elemental zinc were 10 mg for infants and 20 mg for older children (twice
the recommended daily dosage) as zinc gluconate. Zinc or placebo was taken daily for
four months. Both groups received single massive doses of vitamin A (100,000 IU for
infants and 200,000 IU for older children) at enrolment. Immunisations and treatment
for acute illnesses were provided as per WHO guidelines. Children with acute lower
respiratory tract infections received cotrimoxazole. Amoxicillin was substituted if the
child did not respond within three days. Children were sent to hospital if they had signs
and symptoms that warranted referral according to WHO guidelines

Outcomes

Incidence of ALRI
ALRIs were defined by cough and fast breathing or lower chest indrawing as assessed
by the physician; other clinical signs were not taken into account. Fast breathing was
defined as 2 counts of > 50 breaths/minute for infants and > 40 breaths/minute for older
children
Pneumonia was diagnosed either by a combination of cough with crepitations or
bronchial breathing by auscultation or as an episode of ALRI associated with at least
one of lower chest indrawing, convulsions, not able to drink or feed, extreme lethargy,
restlessness or irritability, nasal flaring, or abnormal sleepiness

Notes

Funding: European Union (Contract No IC18CT960045), Norwegian Council of Universities’ Committee for Development Research and Education (PRO 53/96), Department of Child and Adolescent Health and Development (CAH), WHO

Risk of bias
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Bhandari 2002

(Continued)

Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: “children were individually randomised by a simple randomisation scheme
in blocks of eight. The randomisation
scheme was generated by a statistician at
Statens Serum Institut, not otherwise involved with this study, using the SAS software”

Allocation concealment (selection bias)

Quote: “zinc or placebo syrups were prepared and packaged in unbreakable bottles
by GK Pharma ApS Koge, Denmark, who
also labelled bottles with a unique child
identification number according to the randomisation scheme. The supplies of each
child were kept separately in labelled plastic bags. The zinc and placebo were similar
in appearances, taste and packaging. Masking was maintained during the analysis by
coding the groups as A and B”

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Quote: “the supplies for each child were
kept separately in labelled plastic bags”.
“Masking was maintained during analyses
by coding the groups as A or B”

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information to permit judgment

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Exclusion (35%) with their reasons documented. Attrition was 12% in the zinc
group and 8.7% in the control group. Loss
to follow-ups were mainly because they
refused further participation, moved and
died (3 died in the placebo group only)

Selective reporting (reporting bias)

Low risk

We could not locate the protocol of this
study. We could not find the trial registration number of the study. The outcomes
mentioned in the methods were reported
in the results

Other bias

Unclear risk

Sources of funding: Not mentioned if they
had any role in design or results of study

Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

Bobat 2005
Methods

Randomised, double-blind, placebo-controlled trial conducted in Grey’s Hospital in
Pietermaritburg, South Africa. Baseline measurements of plasma HIV-1 viral load and
the percentage of CD4T lymphocytes were established at two study visits before randomisation, and measurements were repeated 3, 6, and 9 months after the start of supplementation

Participants

96 children with HIV-1 infection between the ages of 6 months and 60 months, being
cared for as outpatients at Grey’s Hospital, and not receiving anti-retroviral therapy were
recruited. Pneumonia was diagnosed by history and physical examination, including
chest auscultation, and confirmed by chest radiograph

Interventions

Children either received 10 mg of elemental zinc as sulphate or placebo every day for 6
months. The child’s parent or guardian was given one packet at the first two visits and
two packets at each monthly follow-up visit thereafter, and was instructed on how to
give the tablet

Outcomes

The primary outcome measure was plasma HIV-1 viral load and incidence of pneumonia

Notes

Outpatient management of children with HIV-1 infection is provided by a team of
paediatricians, medical officers, and nurses who care for about 20 to 30 children per
week. After starting zinc or placebo, children were assessed at Grey’s Hospital every 2
weeks for the first month, monthly for 5 months, and a final visit 9 months after zinc
or placebo supplementation started. Pneumonia was diagnosed by history and physical
examination, including chest auscultation, and confirmed by chest radiograph
Funding: This study was funded by the Johns Hopkins Family Health and Child Survival
Cooperative Agreement with the Office of Health, Infectious Diseases, and Nutrition,
Global Health Bureau, US Agency for International Development

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: “Children were block-randomised
in three age strata (6 to 23, 24 to 41, and
42 to 60 months)”; “Randomisation lists
were computer generated at the WHO in
a fixed block size of eight”

Allocation concealment (selection bias)

Quote: “Tablets of zinc sulphate or placebo
were produced by the same manufacturer
(Nutriset, Bierne, France) and supplied in
blister packets of 14 dispersible tablets”;
“An investigator at Grey’s Hospital assigned
children to the treatment groups. The investigators were unaware of the treatment
allocation until follow up was completed”

Unclear risk
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Bobat 2005

(Continued)

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Quote: “An investigator at Grey’s Hospital
assigned children to the treatment groups.
The investigators were unaware of the treatment allocation until follow up was completed.”

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information to permit judgement

Incomplete outcome data (attrition bias)
All outcomes

Low risk

9/105 participants (8.6%) were excluded.
2/46 (4.4%) and 9/50 (18%) participants
did not complete the trial in zinc and
placebo groups, respectively. The reasons
for lost to follow-up were mainly deaths
and refused to participate

Selective reporting (reporting bias)

Low risk

We could not locate the protocol of this
study. We could not find the trial registration number of the study. The outcomes
mentioned in the methods were reported
in the results

Other bias

Low risk

Sources of funding: funding agencies had
no role in views and opinions mentioned
in the study

Brooks 2005
Methods

RCT in which random assignment to zinc or placebo was done with permuted blocks of
variable length between 2 and 8. Placebo was designed to be identical to the zinc syrup in
colour, odour, and taste. The study was conducted at Kamalapur, southeastern Dhaka,
Bangladesh. The medical officer diagnosed pneumonia if crepitations were heard on
inspiration with a respiratory rate greater than 50 breaths per minute; severe pneumonia
was diagnosed if there was also chest indrawing, or at least one other danger sign

Participants

Children aged 60 days to 12 months at the time of enrolment and excluded those with
known or suspected tuberculosis, chronic respiratory or congenital heart disease, or severe
malnutrition requiring hospital admission. Pneumonia was diagnosed if crepitations were
heard on inspiration with a respiratory rate greater than 50 breaths per minute; severe
pneumonia was diagnosed if there was also chest indrawing, or at least one other danger
sign. Children with wheezing or rhonchi with crepitations were also diagnosed with
pneumonia. 809 children were randomly assigned to zinc and 812 to placebo. There
were no significant differences between groups at baseline, except for a slightly higher
proportion of boys in the zinc group. There was no difference between the groups in
serum zinc values at baseline

Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

Brooks 2005

(Continued)

Interventions

Zinc was given orally as a syrup (35 mg zinc acetate per 5 mL). The placebo was nonnutritious and vitamin-free. Compliance required intake of two teaspoons of syrup (10
mL). Children with pneumonia were treated with co-trimoxazole (10 mg/kg trimethoprim, twice daily for 5 days) for pneumonia. Children on antibiotics were assessed within
72 hours of starting treatment; those who did not improve (i.e. the respiratory rate did
not change by more than 5 breaths/minute from baseline) were switched to treatment
with amoxicillin (40 mg/kg, three times daily for 5 days). If oral treatment failed, or if
they had severe pneumonia, children were referred to hospital for parenteral treatment
(ceftriaxone 75 mg/kg intramuscularly per day). Children with only expiratory wheezes
or rhonchi were managed with salbutamol syrup (0.3 mg/kg, 3 times daily), or referred
to hospital for danger signs

Outcomes

Pneumonia incidence. Other outcomes included frequency of other illnesses and mortality

Notes

Sources of funding: The research was funded by Johns Hopkins Family Health and Child
Survival Cooperative Agreement with the US Agency for International Development,
the Swiss Development Corporation, and a cooperative agreement between the US
Agency for International Development (HRN-A-00-96-90005-00) and core donors to
the Centre for Health and Population Research

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: “Random assignment to zinc or
placebo was done with permuted blocks of
variable length between two and eight”

Allocation concealment (selection bias)

Insufficient information to permit judgement

Unclear risk

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Quote: “ACME Laboratories (Dhaka) prepared, labelled and masked the identity
of both preparations. Both placebo and
treatment were designed to be identical in
colour, odour, and taste”; “identity of both
the preparations were masked”

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Quote: “Blinding of FRAs was not affected
because a proportion of children in both
zinc and placebo groups reacted to the taste
such that the treatment could not be distinguished”

Incomplete outcome data (attrition bias)
All outcomes

Loss to follow-up was 9.1%. Withdrawal
from both groups was most commonly attributed to the child’s reaction to the taste

Low risk
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Brooks 2005

(Continued)
of the syrup, which sometimes resulted in
regurgitation. Most of those who withdrew
were young, primarily breast fed infants.
The highest proportion (37·1%) of withdrawals for both groups occurred at age
2 months, with 77·1% younger than 6
months

Selective reporting (reporting bias)

Low risk

We could not locate the protocol of this
study. We could not find the trial registration number of the study. The outcomes
mentioned in the methods were reported
in the results

Other bias

Low risk

Study seems to be free from other biases;
the funding sources had no role in the study
design, data collection, data analysis, interpretation of results, or decision to publish
this research
Funding: The research was funded by
Johns Hopkins Family Health and Child
Survival Cooperative Agreement with the
US Agency for International Development, the Swiss Development Corporation, and a cooperative agreement between
the US Agency for International Development (HRN-A-00-96-90005-00) and core
donors to the Centre for Health and Population Research

Luabeya 2007
Methods

What was the study design?
The study was conducted in northern KwaZulu-Natal Province, South Africa. Children
were enrolled into the study by nurses at five government primary health care clinics.
Pneumonia by maternal report was considered to have occurred if there was a history
of either fast breathing or chest in-drawing. Confirmed pneumonia was defined as an
elevated respiratory rate at rest measured by the fieldworker using WHO/UNICEF
Integrated Management of Childhood Illness guidelines

Participants

Add number of participants. Children eligible for study were 4 to 6 months old. Children
were excluded from the study if they were: less than 60% of median weight-for-age using
United States National Center for Health Statistics standards; had nutritional oedema;
had received vitamin or micronutrient supplements in the previous month; had diarrhoea
for more than seven days at the time of study enrolment; or were enrolled in another study
of a clinical intervention. Confirmed pneumonia was defined as an elevated respiratory
rate at rest measured by the fieldworker using WHO/UNICEF Integrated Management
of Childhood Illness guidelines
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Luabeya 2007

(Continued)

Interventions

The 3 treatment arms were: vitamin A alone; vitamin A plus zinc; and vitamin A, zinc
and multiple micronutrients. All supplements were given daily at home from entry into
the study until 24 months of age

Outcomes

Diarrhoea, pneumonia Incidence? prevalence?

Notes

Funding: Supported by grants from the US National Institute of Health (1 UO1
AI45508-01, 1 K24 AI/HDO1671-01, D43TW05572-01 to Dr Bennish) and the Wellcome Trust (Wellcome 62925 to Dr Bennish and Wellcome 063009 to Dr Van den
Broeck. The sponsor for the study was the host institution, the Africa Centre for Health
and Population Studies, which gave discretion in the investigative team in study design,
data analysis, manuscript preparation, and decisions on manuscript submission and publication

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: “An allocation list was prepared using computer-generated random numbers
and a block size of six”; assignment to the
three treatment arms was done separately
for three cohorts of children stratified by
HIV status of child and mother: HIV-infected children and mothers; HIV-uninfected children of HIV-infected mothers;
and HIV-uninfected children of HIV-uninfected mothers

Allocation concealment (selection bias)

Low risk

Quote: “The manufacturer prepared numbered packs of tablets corresponding to
the allocation list. Children enrolled in the
study were assigned by a study physician
to one of the three study cohorts after results of the HIV tests became available. The
physician then allocated the next pack of
tablets from the blocks assigned to that cohort to the participant”

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Quote: “Investigators, study staff and participants were blind to the treatment assignments”

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Quote: “Investigators, study staff and participants were blind to the treatment assignments”
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(Continued)

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Exclusion (12.7%) and attrition (8.1% in
vitamin A + zinc and 8.9% in vitamin
A group) data were reported along with
their reasons. Thirty-seven children withdrew and one died before any home visits
took place

Selective reporting (reporting bias)

Low risk

The study appears to be free of selective
reporting. Trial Registration
ClinicalTrials.gov NCT00156832. The
outcomes mentioned in the methods were
reported in the results

Other bias

Low risk

Sources of funding: The sponsor for the
study was the host institution, the Africa
Centre for Health and Population Studies, which gave discretion in the investigative team in study design, data analysis,
manuscript preparation, and decisions on
manuscript submission and publication

Penny 2004
Methods

This randomised, double-blind, placebo-controlled, community-based trial was carried
out in Canto Grande, a shanty town on the outskirts of Lima, Peru. The study was
carried out in two phases. During the first phase researchers evaluated the effect of zinc
or multiple micronutrient supplementation on the recovery from persistent diarrhoea.
During the second phase researchers assessed the effect of continued supplementation
on morbidity from new infections during the following 6 months

Participants

412 children aged 6 to 36 months with diarrhoea for 14 days were randomly assigned,
after being stratified for breastfeeding status, to receive two weeks of daily supplementation with one of three indistinguishable supplements: placebo; 20 mg zinc daily as
zinc gluconate (zinc group); or 20 mg zinc daily as zinc gluconate plus a mixture of
other micronutrients, i.e. vitamins and minerals (zinc VM group). A subset of children
consisting of the first 246 children enrolled who intended to remain in the study area
subsequently received the same assigned supplement at one-half the initial daily dose (10
mg zinc daily) and continued under observation for a total of 6 months

Interventions

Supplements were supplied as individual doses of a dry micronutrient mixture with
added sugar, colouring and flavouring agents, which were dissolved in clean water in
participants’ homes and provided as a liquid beverage under the supervision of study
personnel on Monday through Friday and by parents or other caregivers during the
weekends. There were two intervention arms, zinc plus vitamins and minerals who were
given 10 mg of zinc supplementation along with different combinations of mineral and
vitamins. Another interventional arm was given zinc 10 mg and the control group was
not given any supplementation
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Penny 2004

(Continued)

Outcomes

Changes in plasma zinc, haematocrit, haemoglobin, plasma ferritin, pneumonia incidence

Notes

In this review, groups with zinc and placebo are included for analysis. Examination included assessment of hydration status, measurement of rectal temperature and monitoring of respiratory rate, which was counted for 1 minute and repeated if the rate was
greater than age-specific upper limits (50/minute for children aged 6 to 11 months and
40/minute for children aged 11 months). Children were referred to the study physician
for diagnosis and treatment when the fieldworker or caregiver was concerned about the
child’s health status or if the child had any one of several predefined signs of illness,
including fever, presentation or worsening of cough with elevated respiratory rate (i.
e. fieldworker-defined acute lower respiratory infection), persistent diarrhoea, diarrhoea
with signs of dehydration, or vomiting or skin conditions requiring diagnosis
Sources of funding: Supported primarily by the Thrasher Research Fund and the World
Health Organization; additional funds were provided by the University of California
Pacific Rim Program

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

Insufficient information to permit judgement

Allocation concealment (selection bias)

Insufficient information to permit judgement

Unclear risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Quote: “double-masked”

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Quote: “double-masked”

Incomplete outcome data (attrition bias)
All outcomes

High risk

14/81 (17.3%) in zinc and 13/83 (15.7%)
placebo groups lost to follow-up but no reasons were reported

Selective reporting (reporting bias)

Low risk

We could not locate the protocol of this
study. We could not find the trial registration number of the study. The outcomes
mentioned in the methods were reported
in the results

Other bias

Unclear risk

Sources of funding: funding agencies had
no role in views and opinions mentioned
in the study
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Sazawal 1998
Methods

Double-blind RCT in which the loss of follow-up was less than 2% The study was
conducted in a low socioeconomic population of urban India

Participants

Children, 6 to 35 months of age, presenting to a community-based clinic for acute
diarrhoea and before enrolment, a parent of the child was given an explanation of the
study and written informed consent was obtained. The baseline characteristics for the
child-periods included in the analysis were similar between the two groups. The zinc
group had 298 participants and the placebo one had 311

Interventions

Children were randomised to receive either zinc or placebo in a liquid preparation
containing vitamins A (800 units), B1 (0.6 mg), B2 (0.5 mg), B6 (0.5 mg), D3 (100 IU)
, and E (3 mg) and niacinamide (10 mg); the zinc preparation contained zinc gluconate
(10 mg elemental zinc). The liquid preparation 5 mL was given daily for 6 months to
all enrolled children; during diarrhoeal illness this was increased to 10 mL to provide for
excess zinc losses

Outcomes

Incidence and prevalence of ALRI. ALRI was diagnosed as using WHO criteria for
respiratory disease episodes based on fast breathing alone
ALRI was also defined as child having cough and at least one assessment documenting:
a) an elevated respiratory rate more than the age-specific value on both 1-minute estimations; and b) a recorded temperature of more than 101°F or lower chest indrawing

Notes

Funding: This work was supported by grants from the WHO Diarrheal Disease Control
Program, the Thrasher Research Fund, the Johns Hopkins Family Health and Child
Survival Cooperative Agreement with funding from the US Agency for International
Development and the US National Institutes of Health (R29 HD34724). The assistance
of Ms Usha Dhingra and Mr Dharminder Kashyap in data management and of Sandoz
India Ltd for providing the supplements is appreciated

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Quote: ”Randomisation schedules with
permuted blocks of 10 were used for children“

Allocation concealment (selection bias)

Low risk

Quote: ”Supplements were prepared and
coded by Sandoz India Ltd (Mumbai).
Both formulation were liquid preparations,
similar in colour and taste“

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Quote: ”double-blind“; ”The Code, which
was kept by WHO personnel, was not
available to the investigator until the end
of the study; “both formulation were liquid
preparations, similar in colour and taste”
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Sazawal 1998

(Continued)

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information to permit judgement

Incomplete outcome data (attrition bias)
All outcomes

High risk

Exclusion and attrition rates with their reasons were not described in the study

Selective reporting (reporting bias)

Low risk

We could not locate the protocol of this
study. We could not find the trial registration number of the study. The outcomes
mentioned in the methods were reported
in the results

Other bias

Unclear risk

Sandoz India provided the supplements.
Not clear of their role and other funding
agencies

ALRI: acute lower respiratory infection
IU: international unit
RCT: randomised controlled trial
WHO: World Health Organization

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Adhikari 2016

Wrong participants: included children with recurrent respiratory infections

Baqui 2002

Wrong duration: zinc supplementation was given for 2 weeks

Baqui 2003

Wrong diagnosis: ALRI was diagnosed if the child had reported symptoms of cough or difficulty in breathing
with rapid breathing with or without chest indrawing

Bates 1993

Wrong mode of supplementation: zinc supplement was delivered in a fortified drink

Castillo-Duran 1987

Wrong duration; wrong outcomes: zinc was supplemented for 60 days; did not study effects on diarrhoea or
respiratory illnesses

Chandyo 2010

Wrong duration: duration of intervention was 2 weeks

Feiken 2014

Wrong duration: duration of intervention was 10 days

Larson 2010

Wrong diagnosis: did not use this review’s specific ARI definition
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Lind 2004

Wrong diagnosis: considered ‘cough and fever’ as ALRI outcome

Lira 1998

Wrong intervention and outcomes: infants were recruited and supplemented from birth; short course supplementation was provided; only cough was reported

Long 2006

Wrong outcome: respiratory tract infection outcomes were defined as the occurrence of cough alone, cough
and fever, or cough and rapid respiratory rate as reported by the mother

Malik 2014

Wrong diagnosis: considered “cough or cold with or without fever. ALRI was diagnosed if the child had
symptoms of cough with difficult and/or rapid breathing or chest indrawing as informed by the caregiver” as
ALRI

Mazoomar 2010

Wrong diagnosis: considered caregiver’s report of cough or difficulty in breathing along with rapid breathing

McDonald 2015

Wrong population: infants aged less than 2 months at start of intervention (5 to 7 weeks)

Ninh 1996

Wrong diagnosis: respiratory outcome was cough and fever

Osendarp 2002

Wrong population: Infants were recruited and supplemented from 4 weeks of age

Rahman 2001

Wrong duration: supplementation was given for 2 weeks only

Reul 1997

Wrong diagnosis: respiratory infections were defined as the presence of at least two of the following symptoms:
runny nose, cough, wheezing, difficulty breathing, or fever

Richard 2006

Wrong diagnosis: ALRI was reported by parent as presence of cough and rapid respiration

Rosado 1997

Wrong diagnosis: respiratory illness was presence of runny nose, common cold, sore throat or cough

Roy 1999

Wrong duration: zinc supplementation period was 2 weeks

Sampaio 2013

Wrong diagnosis: study used Brazilian Ministry of Health Criteria as ARI definition

Sanchez 2014

Wrong diagnosis: presence of two or more of the following symptoms as ARI: “Cough, runny nose, shortness
of breath and sore throat two or more days duration”

Sempértegui 1996

Wrong duration: zinc supplementation period was 60 days

Soofi 2013

Wrong diagnosis: definition of ARI: “ Signs (fast breathing, chest indrawing) of acute respiratory illness were
recorded as reported by the mother. An acute respiratory illness episode was defined as a minimum of 2 days
with signs followed by a significant interval of at least 7 days”

Sur 2003

Wrong population: Infants were recruited and supplemented from within 7 days of birth

Taneja 2009

Wrong population: zinc supplementation was given to infants between 2 to 4 weeks and 12 months of age
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Tielsch 2007

Wrong diagnosis and population: trial was on children aged 1 to 35 months with data not stratified by age,
ARTI: episodes of acute respiratory illness were defined as one or more consecutive days of fever, cough, or
difficulty breathing, with all three symptoms on at least 1 day during the episode and at least 7 days between
episodes

Umeta 2000

Wrong outcomes: cough was only reported respiratory outcome

Vakili 2009

Wrong population: children included older than review’s specified cut off (78 to 120 months)

ALRI: acute lower respiratory infection
ARI: acute respiratory infection
ARTI: acute respiratory tract infection
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DATA AND ANALYSES

Comparison 1. Zinc supplementation vs placebo

Outcome or subgroup title
1 Pneumonia incidence
1.1 Diagnosis based on agespecific fast breathing with or
without lower chest indrawing
1.2 Diagnosis based agespecific fast breathing and
confirmed by chest examination
or chest radiograph
2 Pneumonia prevalence

No. of
studies

No. of
participants

6
4

5193
1932

Risk Ratio (Fixed, 95% CI)
Risk Ratio (Fixed, 95% CI)

0.87 [0.81, 0.94]
0.95 [0.86, 1.06]

4

3261

Risk Ratio (Fixed, 95% CI)

0.79 [0.71, 0.88]

1

609

Risk Ratio (Fixed, 95% CI)

0.59 [0.35, 0.99]

Statistical method

Effect size

Analysis 1.1. Comparison 1 Zinc supplementation vs placebo, Outcome 1 Pneumonia incidence.
Review:

Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months

Comparison: 1 Zinc supplementation vs placebo
Outcome: 1 Pneumonia incidence

Study or subgroup

Favours experimental

Placebo

log [Risk Ratio]

Risk Ratio

N

N

(SE)

IV,Fixed,95% CI

Weight

Risk Ratio
IV,Fixed,95% CI

1 Diagnosis based on age-specific fast breathing with or without lower chest indrawing
Bhandari 2002

621

621

-0.0202 (0.067)

32.7 %

0.98 [ 0.86, 1.12 ]

Luabeya 2007

113

113

0.191 (0.358)

1.1 %

1.21 [ 0.60, 2.44 ]

80

79

-0.128 (0.131)

8.6 %

0.88 [ 0.68, 1.14 ]

149

156

-0.117 (0.137)

7.8 %

0.89 [ 0.68, 1.16 ]

963

969

50.3 %

0.95 [ 0.86, 1.06 ]

Penny 2004
Sazawal 1998

Subtotal (95% CI)

Heterogeneity: Chi2 = 1.24, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
2 Diagnosis based age-specific fast breathing and confirmed by chest examination or chest radiograph
Bhandari 2002

620

620

-0.301 (0.142)

7.3 %

0.74 [ 0.56, 0.98 ]

Bobat 2005 (1)

46

50

-0.288 (0.158)

5.9 %

0.75 [ 0.55, 1.02 ]

809

812

-0.1863 (0.0655)

34.3 %

0.83 [ 0.73, 0.94 ]

Brooks 2005

0.01

0.1

Favours zinc

1

10

100

Favours placebo

(Continued . . . )
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(. . .
Study or subgroup

Favours experimental

Placebo

log [Risk Ratio]

Risk Ratio

N

N

(SE)

IV,Fixed,95% CI

149

155

-0.5798 (0.2546)

1624

Sazawal 1998

Subtotal (95% CI)

Weight

Continued)
Risk Ratio

IV,Fixed,95% CI
2.3 %

0.56 [ 0.34, 0.92 ]

1637

49.7 %

0.79 [ 0.71, 0.88 ]

2606

100.0 %

0.87 [ 0.81, 0.94 ]

Heterogeneity: Chi2 = 2.71, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 4.29 (P = 0.000018)

Total (95% CI)

2587

Heterogeneity: Chi2 = 9.74, df = 7 (P = 0.20); I2 =28%
Test for overall effect: Z = 3.66 (P = 0.00025)
Test for subgroup differences: Chi2 = 5.78, df = 1 (P = 0.02), I2 =83%

0.01

0.1

1

Favours zinc

10

100

Favours placebo

(1) Children with HIV

Analysis 1.2. Comparison 1 Zinc supplementation vs placebo, Outcome 2 Pneumonia prevalence.
Review:

Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months

Comparison: 1 Zinc supplementation vs placebo
Outcome: 2 Pneumonia prevalence

Study or subgroup

Zinc

Placebo

log [Risk Ratio]

Risk Ratio

N

N

(SE)

IV,Fixed,95% CI

Sazawal 1998

298

311

-0.528 (0.266)

Total (95% CI)

298

311

Weight

Risk Ratio
IV,Fixed,95% CI

100.0 %

0.59 [ 0.35, 0.99 ]

100.0 %

0.59 [ 0.35, 0.99 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable

0.01

0.1

Favours zinc

1

10

100

Favours placebo
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ADDITIONAL TABLES
Table 1. Zinc supplement schedule and duration

Study

Supplement

Schedule

Duration

Surveillance

Zinc

Control

Bhandari 2002

Zinc gluconate
10 mg

Both groups vitamin Daily
A

4 months

Once weekly

Bobat 2005

Zinc sulphate
10 mg

Placebo

Daily

6 months

Every 2 weeks

Brooks 2005

Zinc acetate 35 mg Placebo
to infants
70 mg to children
aged > 12 months

Weekly

12 months

Once weekly

Luabeya 2007

Zinc gluconate
10 mg

Both groups vitamin Daily
A

(Continued until
months of age)

Penny 2004

Zinc gluconate
10 mg

Placebo

Daily

6 months

Once weekly

Sazawal 1998

Zinc gluconate
10 mg

Placebo

Daily

4 months

Every 5th day

24 Once weekly

APPENDICES
Appendix 1. Previous search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, issue 2), which contains
the Acute Respiratory Infections Group’s Specialised Register, MEDLINE (1966 to January Week 2, 2010), Embase (1974 to January
2010) and LILACS (1985 to January 2010).
We used the following search strategy to search MEDLINE and CENTRAL. The search strategy incorporates the search strategy
devised by Boluyt 2008 to identify child studies. Due to the small number of search results we chose not to use a search filter to identify
randomised trials. We adapted the search strategy to search Embase (see Appendix 2) and LILACS (see Appendix 3).

MEDLINE (Ovid)
1 exp Pneumonia/
2 pneumon*.tw.
3 lower respiratory tract infection*.tw.
4 lower respiratory infection*.tw.
5 lrti.tw.
6 or/1-5
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7 Zinc/
8 (zinc or zn).tw,nm.
9 or/7-8
10 exp Infant/
11 (infant* or infancy or newborn* or baby* or babies or neonat* or preterm* or prematur*).tw.
12 exp Child/
13 (child* or schoolchild* or school age* or preschool* or kid or kids or toddler*).tw.
14 Adolescent/
15 (adoles* or teen* or boy* or girl*).tw.
16 Minors/
17 Puberty/
18 (minor* or pubert* or pubescen*).tw.
19 exp Pediatrics/
20 (pediatric* or pediatric*).tw.
21 exp Schools/
22 (nursery school* or kindergar* or primary school* or secondary school* or elementary school* or high school* or highschool*).tw.
23 or/10-22
24 6 and 9 and 23
Embase search strategy
14. #5 AND #9 AND #13
13. #10 OR #11 OR #12
12. child*:ab,ti OR schoolchild*:ab,ti OR preschool*:ab,ti OR kid:ab,ti OR kids:ab,ti OR toddler*:ab,ti OR pediatric*:ab,ti OR
paediatric*:ab,ti OR kindergar*:ab,ti OR (school* NEAR/2 (nursery OR primary OR elementary OR age*)):ab,ti
11. infant*:ab,ti OR infancy:ab,ti OR newborn*:ab,ti OR baby*:ab,ti OR babies:ab,ti OR neonat*:ab,ti
OR preterm*:ab,ti OR prematur*:ab,ti
10. ’infant’/exp OR ’child’/exp OR ’pediatrics’/exp OR ’school’/exp
9. #6 OR #7 OR #8
8. zinc:ab,ti OR zn:ab,ti
7. ’gluconate zinc’/exp
6. ’zinc’/exp
5. #1 OR #2 OR #3 OR #4
4. ’lower respiratory tract infection’:ab,ti OR ’lower respiratory tract infections’:ab,ti OR
’lower respiratory infection’:ab,ti OR ’lower respiratory infections’:ab,ti OR lrti:ab,ti
3. ’lower respiratory tract infection’/de
2. pneumon*:ab,ti
1. ’pneumonia’/exp
LILACS search strategy
pneumon$ or namonia or pulmonia or neumonia [Words] and zinc$ or cinc [Words]
“PNEUMONIA” [Subject descriptor] and “ZINC” [Subject descriptor]
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Appendix 2. MEDLINE (Ovid) search strategy
1 exp Pneumonia/
2 (pneumon* or bronchopneumon* or pleuropneumon*).tw.
3 ((respiratory tract infect* or respiratory infect*) adj3 lower).tw.
4 (lower respiratory adj3 infect*).tw.
5 lrti.tw.
6 or/1-5
7 Zinc/
8 (zinc* or zn).tw,nm.
9 Dietary Supplements/
10 trace elements/ or zinc/
11 Micronutrients/
12 exp Zinc Compounds/
13 ((essential or trace) adj1 (mineral* or nutrient*)).tw.
14 micronutrient*.tw.
15 or/7-14
16 6 and 15

Appendix 3. Embase.com search strategy
#24 #15 AND #23
#23 #18 NOT #22
#22 #19 NOT #21
#21 #19 AND #20
#20 ’human’/de AND [embase]/lim
#19 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#18 #16 OR #17
#17 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR trial:ti OR (doubl* NEXT/1
blind*):ab,ti
#16 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#15 #6 AND #14
#14 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#13 micronutrient*:ab,ti
#12 ((essential OR trace) NEAR/1 (mineral* OR nutrient*)):ab,ti
#11 ’zinc derivative’/de
#10 ’trace element’/exp
#9 ’diet supplementation’/de
#8 zinc*:ab,ti OR zn:ab,ti
#7 ’zinc’/de
#6 #1 OR #2 OR #3 OR #4 OR #5
#5 lrti:ab,ti
#4 ’lower respiratory tract infection’:ab,ti OR ’lower respiratory tract infections’:ab,ti OR ’lower respiratory infection’:ab,ti OR ’lower
respiratory infections’:ab,ti
#3 ’lower respiratory tract infection’/de
#2 pneumon*:ab,ti OR bronchopneumon*:ab,ti OR pleuropneumon*:ab,ti
#1 ’pneumonia’/exp
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Appendix 4. LILACS (Virtual Health Library) search strategy
> Search > (MH:pneumonia OR pneumon$ OR Neumonía OR MH:C08.381.677$ OR MH:C08.730.610$ OR Pulmonía OR
Bronchopneumonia OR Bronconeumonía OR Broncopneumonia OR Pleuropneumonia OR Pleuroneumonía OR MH:“Respiratory
Tract Infections” OR “Infecciones del Sistema Respiratorio” OR “Infecções Respiratórias” OR “lower respiratory infection” OR “lower
respiratory infections” OR “lower respiratory tract infection” OR “lower respiratory tract infections” OR lrti) AND (MH:zinc OR zinc
OR zinco OR zn OR MH:“Zinc Compounds” OR MH:D01.975$ OR MH:“Dietary Supplements” OR “Suplementos Dietéticos”
OR “Suplementos Dietéticos” OR MH:“Trace Elements” OR Oligoelementos OR MH:Micronutrients OR Micronutrientes)

Appendix 5. CINAHL (EBSCO) search strategy
S23 S13 and S22
S22 S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21
S21 (MH “Quantitative Studies”)
S20 TI placebo* OR AB placebo*
S19 (MH “Placebos”)
S18 TI random* OR AB random*
S17 TI ((singl* or doubl* or tripl* or trebl*) N1 (blind* or mask*)) OR AB ((singl* or doubl* or tripl* or trebl*) N1 (blind* or mask*))
S16 TI clinic* trial* OR AB clinic* trial*
S15 PT clinical trial Search modes S14 (MH “Clinical Trials+”)
S13 S4 and S12
S12 S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TI micronutrient* OR AB micronutrient*
S10 TI ((essential or trace) N1 (mineral* or nutrient*)) OR AB ((essential or trace) N1 (mineral* or nutrient*))
S9 (MH “Micronutrients”)
S8 (MH “Trace Elements”)
S7 (MH “Dietary Supplements”)
S6 TI (zinc* or zn) OR AB (zinc* or zn)
S5 (MH “Zinc”) OR (MH “Zinc Compounds+”)
S4 S1 or S2 or S3
S3 TI (lower respiratory tract infect* or lower respiratory infect* or lrti) OR AB (lower respiratory tract infect* or lower respiratory
infect* or lrti)
S2 TI (pneumon* or bronchopneumon* or pleuropneumon*) OR AB (pneumon* or bronchopneumon* or pleuropneumon*)
S1 (MH “Pneumonia+”)

Appendix 6. Web of Science (Thomson Reuters)
Topic=(pneumonia or bronchopneumonia or pleuropneumonia) AND Topic=(zinc)
Refined by: Topic=(random* or placebo* or clinical trial* or double blind*)
Timespan=All Years. Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC.
Lemmatization=Off
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FEEDBACK

Feedback comment by Joseph L. Mathew, 10 February 2011

Summary
Please note the following feedback.
1. The forest plot in Analysis 1.1 shows that participants in the trial by Bhandari et al, have been split to present two different outcomes.
Half the participants in each arm are included for the outcome “Diagnosis based on age-specific fast breathing with or without lower
chest indrawing” and half for the outcome “Diagnosis based age-specific fast breathing AND confirmed by chest examination or chest
radiograph”. Both outcomes have been presented as subgroup analysis in the same forest plot; although the trial report mentions that
both outcomes were evaluated in all participants. Please confirm whether the procedure adopted in this review is standard practice; and
the purpose of doing this.
Answer: We presented the findings after dividing the participants equally in the four cells so that participants do not repeat across
analysis. The number of participants were 1241 in each group and we divided them as 620/621 for each of the four cells).
2. A similar adjustment seems to have been made with the participants in the trial by Sazawal et al.
Answer: Adjusted
3. The reference section mentions three citations under Sazawal 1998a; and one under Sazawal 1998b. The third citation in Sazawal
1998a is the same as Sazawal 1998b. Further, none of the citations reports 3300 participants in the trial; whereas this is the number
included in the meta-analysis. Sazawal’s 1995 publication in the New England Journal of Medicine mentions 937 participants; while
the 1998 publication in Pediatrics reported 609 participants. Please confirm the basis for using the numbers in the meta-analysis.
Answer: Those were the two parts of the same study. We have now merged it and presented it as one study.
4. The meta-analysis has pooled data from children with HIV infection, along with otherwise healthy children. While it seems reasonable
to pool children with unknown HIV status with otherwise healthy children, it would be better to analyse HIV infected children
separately since pneumonia in immuno-compromised children could be quite different from otherwise healthy children.
Answer: In the text only, we presented the results on removing Bobat trial as well.
Submitter agrees with default conflict of interest statement:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
We thank Dr Mathew for these comments.
Contributors
Joseph L. Mathew

WHAT’S NEW

Date

Event

Description

25 January 2017

Amended

Minor data transcription error corrected
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HISTORY

Date

Event

Description

26 October 2015

New search has been performed

A new review author joined us to update this review. We
excluded 11 new trials (Adhikari 2016; Chandyo 2010;
Feiken 2014; Larson 2010; Malik 2014; Mazoomar
2010; McDonald 2015; Sampaio 2013; Sanchez 2014;
Soofi 2013; Vakili 2009).

26 October 2015

New citation required but conclusions have not Our conclusions remain unchanged.
changed

26 October 2015

New search has been performed

Searches updated,

8 May 2013

New search has been performed

Searches conducted

10 February 2012

Amended

Authors replied to Feedback comment

8 August 2011

Feedback has been incorporated

Feedback added to review.
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External sources
• No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW
We have added mandatory sections such as subgroup analysis and sensitivity analysis for this update.

INDEX TERMS
Medical Subject Headings (MeSH)
Gluconates [administration & dosage]; Pneumonia [epidemiology; ∗ prevention & control]; Randomized Controlled Trials as Topic;
Zinc Acetate [administration & dosage]; Zinc Compounds [∗ administration & dosage]; Zinc Sulfate [administration & dosage]

MeSH check words
Child, Preschool; Humans; Infant
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